Loading…
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2.3B | $160M | $128M | $57M | 23.7% | 59.0% | 1.8% |
| 2024 | $1.5B | $79M | $126M | $198M | 26.4% | 69.3% | - |
| 2023 | $872M | $-20M | $-24M | $47M | -6.8% | 65.5% | - |
| 2022 | $527M | $-61M | $-66M | $-34M | -21.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 526.92 | 872 | 1,476.51 | 2,347.64 |
| Cost Of Revenue | 118.19 | 157.05 | 303.38 | 614.26 |
| Gross Profit | 408.72 | 714.95 | 1,173.13 | 1,733.38 |
| Operating Expense | 477.42 | 744.40 | 1,111.23 | 1,627.77 |
| Operating Income | -68.70 | -29.45 | 61.90 | 105.61 |
| EBITDA | -61.22 | -19.94 | 78.99 | 160.12 |
| EBIT | -68.70 | -29.45 | 61.90 | 105.61 |
| Pretax Income | -65.71 | -21.57 | 71.71 | 123.92 |
| Tax Provision | -0.03 | 1.98 | -54.33 | -4.44 |
| Net Income | -65.68 | -23.55 | 126.04 | 128.37 |
| Net Income Common Stockholders | -65.68 | -23.55 | 126.04 | 128.37 |
| Total Expenses | 595.61 | 901.45 | 1,414.61 | 2,242.02 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Research And Development | 29.24 | 48.23 | 78.82 | 149.30 |
| Selling General And Administration | 370.78 | 576.32 | 846.61 | 1,192.02 |
| Normalized EBITDA | -61.22 | -19.94 | 78.99 | 155.68 |
| Normalized Income | -65.68 | -23.55 | 126.04 | 0 |
| Basic EPS | -0.32 | -0.11 | 0.58 | 0.57 |
| Diluted EPS | -0.32 | -0.11 | 0.53 | 0.51 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0.93 |
| Tax Rate For Calcs | 0 | 0.21 | 0.21 | 0.21 |
| Total Unusual Items | 0.07 | 0 | 0 | 4.44 |
| Total Unusual Items Excluding Goodwill | 0.07 | 0 | 0 | 4.44 |
| Net Income From Continuing Operation Net Minority Interest | -65.68 | -23.55 | 126.04 | 128.37 |
| Reconciled Depreciation | 7.47 | 9.52 | 17.09 | 54.50 |
| Reconciled Cost Of Revenue | 118.19 | 157.05 | 303.38 | 614.26 |
| Net Interest Income | 0 | 0 | 0 | 0 |
| Net Income From Continuing And Discontinued Operation | -65.68 | -23.55 | 126.04 | 128.37 |
| Total Operating Income As Reported | -68.70 | -29.45 | 61.90 | 105.61 |
| Diluted Average Shares | 204.52 | 209.34 | 236.81 | 258.23 |
| Basic Average Shares | 204.52 | 209.34 | 215.94 | 224.96 |
| Diluted NI Availto Com Stockholders | -65.68 | -23.55 | 126.04 | 128.37 |
| Net Income Including Noncontrolling Interests | -65.68 | -23.55 | 126.04 | 128.37 |
| Net Income Continuous Operations | -65.68 | -23.55 | 126.04 | 128.37 |
| Other Income Expense | 2.99 | 7.88 | 9.81 | 18.31 |
| Other Non Operating Income Expenses | 2.99 | 7.88 | 9.81 | 13.87 |
| Gain On Sale Of Security | 0.07 | 0 | 0 | 4.44 |
| Net Non Operating Interest Income Expense | 0 | 0 | 0 | 0 |
| Interest Expense Non Operating | 0 | 0 | 0 | 0 |
| Other Operating Expenses | 77.40 | 119.86 | 185.80 | 286.44 |
| Selling And Marketing Expense | 272.59 | 446.44 | 678.84 | 919.30 |
| General And Administrative Expense | 98.19 | 129.88 | 167.77 | 272.72 |
| Other Gand A | 98.19 | 129.88 | 167.77 | 272.72 |
| Operating Revenue | 526.92 | 872 | 1,476.51 | 2,347.64 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Hims & Hers Health, Inc.this co. | HIMS | $6.1B | 51.63 | 11.06 | 23.7% | 37.26 |
| Spyre Therapeutics, Inc. | SYRE | $6.2B | - | 10.05 | 0.0% | - |
| Cogent Biosciences, Inc. | COGT | $6.1B | - | 10.56 | -51.7% | -15.73 |
| Terns Pharmaceuticals, Inc. | TERN | $6.1B | - | 5.91 | -9.6% | -46.26 |
| Celcuity Inc. | CELC | $5.8B |
| - |
| 57.10 |
| -176.1% |
| -32.74 |
| Mirum Pharmaceuticals, Inc. | MIRM | $5.7B | - | 15.53 | -7.4% | 2666.18 |
| CG Oncology, Inc. | CGON | $5.7B | - | 6.94 | -21.4% | -24.99 |
| Rhythm Pharmaceuticals, Inc. | RYTM | $5.6B | - | 39.69 | -72.8% | -28.64 |
| Scholar Rock Holding Corporation | SRRK | $5.5B | - | 20.46 | -154.0% | -13.21 |
| Peer Median | - | - | 13.05 | -36.5% | -24.99 | |